{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:45:51Z","timestamp":1775155551301,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007156","name":"Innovation and Technology Commission","doi-asserted-by":"publisher","award":["MHP\/005\/20"],"award-info":[{"award-number":["MHP\/005\/20"]}],"id":[{"id":"10.13039\/501100007156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20210324130209023"],"award-info":[{"award-number":["JCYJ20210324130209023"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004377","name":"Hong Kong Polytechnic University","doi-asserted-by":"publisher","award":["P0035421"],"award-info":[{"award-number":["P0035421"]}],"id":[{"id":"10.13039\/501100004377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022720","name":"Health Bureau","doi-asserted-by":"crossref","award":["HMRF 09200576"],"award-info":[{"award-number":["HMRF 09200576"]}],"id":[{"id":"10.13039\/100022720","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02219-6","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:18:53Z","timestamp":1770286733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor heterogeneity index from DCE-MRI for AKT-inhibition responder identification and reveals hot immune microenvironment for patients with breast cancer: a multi-omics analysis of I-SPY2 trial"],"prefix":"10.1186","volume":"28","author":[{"given":"Xinzhi","family":"Teng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingpei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habib","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine Yuen Phin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"El Helali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Defeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2219_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10555-016-9637-x","volume":"35","author":"A Guerrero-Zotano","year":"2016","unstructured":"Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K\/AKT\/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515\u201324. https:\/\/doi.org\/10.1007\/s10555-016-9637-x.","journal-title":"Cancer Metastasis Rev"},{"key":"2219_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0014-5793(03)00562-3","volume":"546","author":"MP Scheid","year":"2003","unstructured":"Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B\/Akt. FEBS Lett. 2003;546:108\u201312. https:\/\/doi.org\/10.1016\/S0014-5793(03)00562-3.","journal-title":"FEBS Lett"},{"key":"2219_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pharmthera.2016.12.001","volume":"172","author":"JS Brown","year":"2017","unstructured":"Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 2017;172:101\u201315. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.12.001.","journal-title":"Pharmacol Ther"},{"key":"2219_CR4","doi-asserted-by":"publisher","unstructured":"Rugo HS, Olopade OI, DeMichele A, Yau C, van \u2019t Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive randomization of veliparib\u2013carboplatin treatment in breast cancer. N Engl J Med. 2016;375:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1513749","DOI":"10.1056\/NEJMoa1513749"},{"key":"2219_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1513750","volume":"375","author":"JW Park","year":"2016","unstructured":"Park JW, Liu MC, Yee D, Yau C, van \u2019t Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Liu MC, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1513750.","journal-title":"N Engl J Med"},{"key":"2219_CR6","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.19.01027","volume":"38","author":"AJ Chien","year":"2020","unstructured":"Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, van\u2019t Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA. Esserman, on behalf of I-SPY 2 Consortium, MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2\u2013positive and\/or hormone receptor\u2013negative breast cancers in the I-SPY 2 trial. J Clin Oncol. 2020;38:1059\u201369. https:\/\/doi.org\/10.1200\/JCO.19.01027.","journal-title":"J Clin Oncol"},{"key":"2219_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.141.","journal-title":"Nat Rev Clin Oncol"},{"key":"2219_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.annonc.2020.03.295","volume":"31","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Wang H, Wu J, Chen C, Yuan Q, Huang W, Li T, Xi S, Hu Y, Zhou Z, Xu Y, Li G, Li R. Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer. Ann Oncol. 2020;31:760\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.295.","journal-title":"Ann Oncol"},{"key":"2219_CR9","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.3390\/cancers14225507","volume":"14","author":"W Ming","year":"2022","unstructured":"Ming W, Li F, Zhu Y, Bai Y, Gu W, Liu Y, Liu X, Sun X, Liu H. Unsupervised analysis based on DCE-MRI radiomics features revealed three novel breast cancer subtypes with distinct clinical outcomes and biological characteristics. Cancers. 2022;14:5507. https:\/\/doi.org\/10.3390\/cancers14225507.","journal-title":"Cancers"},{"key":"2219_CR10","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1002\/jmri.26291","volume":"49","author":"D Leithner","year":"2019","unstructured":"Leithner D, Moy L, Morris EA, Marino MA, Helbich TH, Pinker K. Abbreviated MRI of the breast: Does it provide value? J Magn Reson Imaging JMRI. 2019;49:e85\u2013100. https:\/\/doi.org\/10.1002\/jmri.26291.","journal-title":"J Magn Reson Imaging JMRI"},{"key":"2219_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00203-7","volume":"6","author":"W Li","year":"2020","unstructured":"Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA-T, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. Npj Breast Cancer. 2020;6:1\u20136. https:\/\/doi.org\/10.1038\/s41523-020-00203-7.","journal-title":"Npj Breast Cancer"},{"key":"2219_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-021-00247-3","volume":"7","author":"J Xiao","year":"2021","unstructured":"Xiao J, Rahbar H, Hippe DS, Rendi MH, Parker EU, Shekar N, Hirano M, Cheung KJ, Partridge SC. Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis. Npj Breast Cancer. 2021;7:1\u20139. https:\/\/doi.org\/10.1038\/s41523-021-00247-3.","journal-title":"Npj Breast Cancer"},{"key":"2219_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1148\/radiol.2020191453","volume":"296","author":"T Bismeijer","year":"2020","unstructured":"Bismeijer T, van der Velden BHM, Canisius S, Lips EH, Loo CE, Viergever MA, Wesseling J, Gilhuijs KGA, Wessels LFA. Radiogenomic analysis of breast cancer by linking MRI phenotypes with tumor gene expression. Radiology. 2020;296:277\u201387. https:\/\/doi.org\/10.1148\/radiol.2020191453.","journal-title":"Radiology"},{"key":"2219_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.18383\/j.tom.2020.00006","volume":"6","author":"N Onishi","year":"2020","unstructured":"Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM. Impact of MRI protocol adherence on prediction of pathological complete response in the I-SPY 2 neoadjuvant breast cancer trial. Tomography. 2020;6:77\u201385. https:\/\/doi.org\/10.18383\/j.tom.2020.00006.","journal-title":"Tomography"},{"key":"2219_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga J-Y, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M. MINDACT Investigators, 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1602253.","journal-title":"N Engl J Med"},{"key":"2219_CR16","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jamasurg.2022.4118","volume":"157","author":"M Osdoit","year":"2022","unstructured":"Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen Y-Y, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA. Association of residual ductal carcinoma in situ with breast cancer recurrence in the neoadjuvant I-SPY2 trial. JAMA Surg. 2022;157:1034\u201341. https:\/\/doi.org\/10.1001\/jamasurg.2022.4118.","journal-title":"JAMA Surg"},{"key":"2219_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/radiol.2015150013","volume":"279","author":"NM Hylton","year":"2016","unstructured":"Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD. For the ACRIN 6657 trial team and I-SPY 1 TRIAL Investigators, neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival\u2014Results from the ACRIN 6657\/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016;279:44\u201355. https:\/\/doi.org\/10.1148\/radiol.2015150013.","journal-title":"Radiology"},{"key":"2219_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, Depeursinge A, Desseroit M-C, Dinapoli N, Dinh CV, Echegaray S, Naqa IE, Fedorov AY, Gatta R, Gillies RJ, Goh V, G\u00f6tz M, Guckenberger M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losneg\u00e5rd A, Maier-Hein KH, Morin O, M\u00fcller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Socarras Fernandez J, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, L\u00f6ck S. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328\u201338. https:\/\/doi.org\/10.1148\/radiol.2020191145.","journal-title":"Radiology"},{"key":"2219_CR19","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RGH, Fillion-Robin J-C, Pieper S, Aerts HJWL. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0339.","journal-title":"Cancer Res"},{"key":"2219_CR20","doi-asserted-by":"publisher","first-page":"10035","DOI":"10.1038\/s41598-022-14178-x","volume":"12","author":"X Teng","year":"2022","unstructured":"Teng X, Zhang J, Zwanenburg A, Sun J, Huang Y, Lam S, Zhang Y, Li B, Zhou T, Xiao H, Liu C, Li W, Han X, Ma Z, Li T, Cai J. Building reliable radiomic models using image perturbation. Sci Rep. 2022;12:10035. https:\/\/doi.org\/10.1038\/s41598-022-14178-x.","journal-title":"Sci Rep"},{"key":"2219_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41598-018-36938-4","volume":"9","author":"A Zwanenburg","year":"2019","unstructured":"Zwanenburg A, Leger S, Agolli L, Pilz K, Troost EGC, Richter C, L\u00f6ck S. Assessing robustness of radiomic features by image perturbation. Sci Rep. 2019;9:614. https:\/\/doi.org\/10.1038\/s41598-018-36938-4.","journal-title":"Sci Rep"},{"key":"2219_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41523-017-0025-7","volume":"3","author":"DM Wolf","year":"2017","unstructured":"Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, van Olopade O. T Veer, DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib\/carboplatin response in the I-SPY 2 breasT cancer trial. NPJ Breast Cancer. 2017;3:31. https:\/\/doi.org\/10.1038\/s41523-017-0025-7.","journal-title":"NPJ Breast Cancer"},{"key":"2219_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer Immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint Blockade. Cell Rep. 2017;18:248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019.","journal-title":"Cell Rep"},{"key":"2219_CR24","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1158\/1078-0432.CCR-18-3524","volume":"25","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue M-Z, Ruan M, Wang H, Zhao J, Li Q, Wang P, Shi L, Yang W-T, Huang W, Hu X, Yu K-D, Huang S, Bertucci F, Jiang Y-Z. Shao, on behalf of AME breast cancer collaborative group, multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3524.","journal-title":"Clin Cancer Res"},{"key":"2219_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Saut\u00e8s-Fridman C, Fridman WH, de Reyni\u00e8s A. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. https:\/\/doi.org\/10.1186\/s13059-016-1070-5.","journal-title":"Genome Biol"},{"key":"2219_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","volume":"375","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375:65\u201374. https:\/\/doi.org\/10.1056\/NEJMra1510061.","journal-title":"N Engl J Med"},{"key":"2219_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.970885","author":"M Peng","year":"2022","unstructured":"Peng M Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile. Front Immunol. (2022). https:\/\/doi.org\/10.3389\/fimmu.2022.970885.","journal-title":"Front Immunol"},{"key":"2219_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872010","author":"SA Atallah-Yunes","year":"2022","unstructured":"Atallah-Yunes SA, Robertson MJ Cytokine based immunotherapy for cancer and lymphoma: biology, challenges and future perspectives. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.872010.","journal-title":"Front Immunol"},{"key":"2219_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1189\/jlb.5RU0714-360RR","volume":"97","author":"M Fabbi","year":"2015","unstructured":"Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol. 2015;97:665\u201375. https:\/\/doi.org\/10.1189\/jlb.5RU0714-360RR.","journal-title":"J Leukoc Biol"},{"key":"2219_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","volume":"9","author":"Z Zeng","year":"2022","unstructured":"Zeng Z, Lan T, Wei Y, Wei X. CCL5\/CCR5 axis in human diseases and related treatments. Genes Dis. 2022;9:12\u201327. https:\/\/doi.org\/10.1016\/j.gendis.2021.08.004.","journal-title":"Genes Dis"},{"key":"2219_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13059-019-1716-1","volume":"20","author":"K Korthauer","year":"2019","unstructured":"Korthauer K, Kimes PK, Duvallet C, Reyes A, Subramanian A, Teng M, Shukla C, Alm EJ, Hicks SC. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 2019;20:118. https:\/\/doi.org\/10.1186\/s13059-019-1716-1.","journal-title":"Genome Biol"},{"key":"2219_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O\u2019Grady N, Basu A, Delson A, Copp\u00e9 JP, Lu R, Braun J, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ. Van\u2019t Veer, redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022;40:609\u2013e6236. https:\/\/doi.org\/10.1016\/j.ccell.2022.05.005.","journal-title":"Cancer Cell"},{"key":"2219_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd.2017.244","volume":"17","author":"P Morgan","year":"2018","unstructured":"Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, Hamr\u00e9n B, Johnson A, March RE, Matcham J, Mettetal J, Nicholls DJ, Platz S, Rees S, Snowden MA, Pangalos MN. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018;17:167\u201381. https:\/\/doi.org\/10.1038\/nrd.2017.244.","journal-title":"Nat Rev Drug Discov"},{"key":"2219_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10434-001-0549-8","volume":"8","author":"L Esserman","year":"2001","unstructured":"Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001;8:549\u201359. https:\/\/doi.org\/10.1007\/s10434-001-0549-8.","journal-title":"Ann Surg Oncol"},{"key":"2219_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1023\/B:BREA.0000010700.11092.f4","volume":"83","author":"L Martincich","year":"2004","unstructured":"Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, Gatti M, Biglia N, Sarotto I, Sismondi P, Regge D, Aglietta M. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat. 2004;83:67\u201376. https:\/\/doi.org\/10.1023\/B:BREA.0000010700.11092.f4.","journal-title":"Breast Cancer Res Treat"},{"key":"2219_CR36","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3390\/cancers12082226","volume":"12","author":"I Shihab","year":"2020","unstructured":"Shihab I, Khalil BA, Elemam NM, Hachim IY, Hachim MY, Hamoudi RA. Maghazachi, Understanding the role of innate immune cells and identifying genes in breast cancer microenvironment. Cancers. 2020;12:2226. https:\/\/doi.org\/10.3390\/cancers12082226.","journal-title":"Cancers"},{"key":"2219_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13046-020-01788-4","volume":"40","author":"H Huang","year":"2021","unstructured":"Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, Ni C. The Immunomodulatory effects of endocrine therapy in breast cancer. J Exp Clin Cancer Res. 2021;40:19. https:\/\/doi.org\/10.1186\/s13046-020-01788-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"2219_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41523-020-00189-2","volume":"6","author":"DM Wolf","year":"2020","unstructured":"Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Jesus M, Magbanua M, O\u2019Grady N, Hirst G, 2 I-SPY, Investigators TRIAL, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF. Van \u2018T Veer, mechanism of action biomarkers predicting response to AKT Inhibition in the I-SPY 2 breast cancer trial. Npj Breast Cancer. 2020;6:48. https:\/\/doi.org\/10.1038\/s41523-020-00189-2.","journal-title":"Npj Breast Cancer"},{"key":"2219_CR39","doi-asserted-by":"publisher","first-page":"21806","DOI":"10.18632\/oncotarget.15586","volume":"8","author":"RA Hampsch","year":"2017","unstructured":"Hampsch RA, Shee K, Bates D, Lewis LD, D\u00e9sir\u00e9 L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW. Therapeutic sensitivity to Rac GTPase Inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer. Oncotarget. 2017;8:21806\u201317. https:\/\/doi.org\/10.18632\/oncotarget.15586.","journal-title":"Oncotarget"},{"key":"2219_CR40","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Moreno HLG, Hu X, Jhaveri K, Krivorotko P, Loibl S, Murillo SM, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS. Capivasertib in hormone receptor\u2013positive advanced breast cancer. N Engl J Med. 2023;388:2058\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2214131.","journal-title":"N Engl J Med"},{"key":"2219_CR41","doi-asserted-by":"publisher","first-page":"101056","DOI":"10.1016\/j.tranon.2021.101056","volume":"14","author":"M Mollaei","year":"2021","unstructured":"Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Chemotherapeutic drugs: cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl Oncol. 2021;14:101056. https:\/\/doi.org\/10.1016\/j.tranon.2021.101056.","journal-title":"Transl Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02219-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02219-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02219-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:18:55Z","timestamp":1770286735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02219-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2219"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02219-6","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves a secondary analysis of data collected from the I-SPY2 trial cohort 1. All participants\u2019 information has been anonymized prior to its inclusion in this study. As a result, the requirement for ethics approval has been waived and the norm or standard of ethics declaration is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to partcipate"}},{"value":"All author consents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal and human rights"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}